← Back to Search

Procedure

EVLP for Lung Transplant (EVLP-CHUM Trial)

N/A

Recruiting

Led By Pasquale Ferraro, MD

Research Sponsored by Centre hospitalier de l'Université de Montréal (CHUM)

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 12 months after transplantation

Awards & highlights

EVLP-CHUM Trial Summary

This trial is testing a new way to clean and prep donor lungs so that they can be safely transplanted. The trial will also study the lungs' inflammatory response before transplant.

Who is the study for?

This trial is for adults over 18 who are on the active waiting list for their first lung transplant and have given informed consent. They must re-confirm consent on the day of transplant and have received patient information sheets beforehand. It's not open to those under 18, without informed consent, or needing mechanical ventilation or ECMO support.Check my eligibility

What is being tested?

The study tests a new technique called Ex Vivo Lung Perfusion (EVLP) which aims to make previously unusable donor lungs safe for transplantation. The process also allows researchers to study inflammatory responses in the lungs before they're transplanted.See study design

What are the potential side effects?

While specific side effects aren't listed, EVLP may carry risks similar to other lung transplant procedures such as infection, rejection of the donor lung, inflammation due to biomarker evaluation processes, and complications from surgery.

EVLP-CHUM Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 12 months after transplantation

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~12 months after transplantation

This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months after transplantation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Measure of survival

Secondary outcome measures

90 day Mortality

Duration of hospital stay

Duration of mechanical ventilation

+2 more

Other outcome measures

Biomarkers

EVLP-CHUM Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: EVLP GroupExperimental Treatment1 Intervention

Recipients receive reconditioned EVLP donor lungs and current standard of care for lung transplant is administered.

Group II: Standard GroupActive Control1 Intervention

Recipients receive standard donor lungs as per current clinical practice. No experimental procedures will be carried out.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

EVLP Group

2011

Completed Phase 1

~10

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Centre hospitalier de l'Université de Montréal (CHUM)Lead Sponsor

366 Previous Clinical Trials

129,587 Total Patients Enrolled

Fondation Pour La Recherche en Chirurgie Thoracique De MontrealUNKNOWN

Centre de Recherche du Centre Hospitalier de l'Université de MontréalOTHER

51 Previous Clinical Trials

94,237 Total Patients Enrolled

Media Library

EVLP (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT02235610 — N/A

Lung Transplant Research Study Groups: Standard Group, EVLP Group

Lung Transplant Clinical Trial 2023: EVLP Highlights & Side Effects. Trial Name: NCT02235610 — N/A

EVLP (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02235610 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current enrollment for this trial?

"Affirmative. According to the information made available on clinicaltrials.gov, this investigation is still in pursuit of participants. It was initially advertised on October 1st 2014 and last updated December 6th 2022; 50 people are sought at a single location."

Answered by AI

Is this trial open to new participants at present?

"Patients are being actively recruited for this trial as per the information posted on clinicaltrials.gov. The study was initiated October 1st 2014 with recent updates to its protocol made December 6th 2022."

Answered by AI

Are octogenarians welcomed to join this experiment?

"Participants must be aged 18 or over, but not yet 65, to qualify for this medical study."

Answered by AI

Am I eligible to volunteer for this investigation?

"In order to be considered for this study, participants should have had a lung transplant and fall within the 18-65 age range. There is an opening for 50 applicants in total."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Use of Ex Vivo Lung Perfusion (EVLP) in Reconditioning Marginal Donor Lungs for Transplantation

2014. "Use of Ex Vivo Lung Perfusion (EVLP) in Reconditioning Marginal Donor Lungs for Transplantation". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02235610.